Compare Amphastar Pharmaceuticals Inc (AMPH) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.44 (market cap $826.08M), while Wheaton Precious Metals Corp trades at $107.14 (market cap $49.85B). The key difference: Wheaton Precious Metals Corp is far larger — about 60.3× Amphastar Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.71% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WPM | |
|---|---|---|
Market Cap | $826.08M | $49.85B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $165.72 |
52-Week Low | $16.87 | $88.32 |
Enterprise Value | $1.22B | $47.69B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Wheaton Precious Metals (WPM) trades at $110.05, down 0.54% on the day, amid a bearish technical signal. The company exhibits strong fundamentals with 2025 revenue of $2.31B, net income of $1.47B, and consistent earnings beats. Analyst consensus is strongly bullish with a $163 price target, though recent news highlights sensitivity to precious metal price volatility.
WPM offers a compelling growth story with robust profitability and positive cash flow, but faces risks from commodity price swings and acquisition integration. The stock's current discount to analyst targets presents a potential opportunity for long-term investors, contingent on stable metal prices and execution of production outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
